Literature DB >> 15341990

Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas.

Jie Jing1, Chun Fu Lien, Sanjay Sharma, Jill Rice, Peter A Brennan, Dariusz C Górecki.   

Abstract

The alpha- and beta- dystroglycan (DG) proteins are involved in epithelial cell development, formation of the basement membrane and maintenance of tissue integrity. Recently, specific changes in the expression patterns of DGs have been described in some cancers. We studied the expression and localisation of alpha- and beta-DG using Western blotting, immunohistochemistry and reverse transcriptase-polymerase chain reaction analyses in samples of normal oral mucosa, oral squamous cell carcinoma (SCC) and cancer cell lines. The alpha- and beta-DG were localised in the basal layers of normal oral mucosa.However, beta-DG expression in cancer tissues showed evidence of aberrant expression, processing and degradation. alpha-DG was altered in all oral cancer samples and cell lines, despite the persistent presence of DG mRNA in cancer cells. Using matrix metalloproteinase (MMP) inhibitors, we determined that beta-DG degradation in carcinoma cell lines can be mediated by MMPs but this process is highly variable, even in cells from the same cancer type. Considering the multifaceted role of DG in epithelial development, it appears that the role of DG degradation in cancer growth and spread, although currently poorly understood, may be important.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341990     DOI: 10.1016/j.ejca.2004.05.018

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

1.  A role of fukutin, a gene responsible for Fukuyama type congenital muscular dystrophy, in cancer cells: a possible role to suppress cell proliferation.

Authors:  Tomoko Yamamoto; Yoichiro Kato; Noriyuki Shibata; Tatsuo Sawada; Makiko Osawa; Makio Kobayashi
Journal:  Int J Exp Pathol       Date:  2008-10       Impact factor: 1.925

2.  Cancer Malignancy Is Correlated with Upregulation of PCYT2-Mediated Glycerol Phosphate Modification of α-Dystroglycan.

Authors:  Fumiko Umezawa; Makoto Natsume; Shigeki Fukusada; Kazuki Nakajima; Fumiya Yamasaki; Hiroto Kawashima; Chu-Wei Kuo; Kay-Hooi Khoo; Takaya Shimura; Hirokazu Yagi; Koichi Kato
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

3.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

4.  Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors.

Authors:  Laura T Martin; Matthew Glass; Eniolami Dosunmu; Paul T Martin
Journal:  Hum Pathol       Date:  2007-07-19       Impact factor: 3.466

5.  Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase.

Authors:  Xingfeng Bao; Motohiro Kobayashi; Shingo Hatakeyama; Kiyohiko Angata; Donald Gullberg; Jun Nakayama; Michiko N Fukuda; Minoru Fukuda
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-08       Impact factor: 11.205

6.  MMP2-9 cleavage of dystroglycan alters the size and molecular composition of Schwann cell domains.

Authors:  Felipe A Court; Desirée Zambroni; Ernesto Pavoni; Cristina Colombelli; Chiara Baragli; Gianluca Figlia; Lydia Sorokin; William Ching; James L Salzer; Lawrence Wrabetz; M Laura Feltri
Journal:  J Neurosci       Date:  2011-08-24       Impact factor: 6.167

7.  Fer kinase regulates cell migration through α-dystroglycan glycosylation.

Authors:  Tohru Yoneyama; Kiyohiko Angata; Xingfeng Bao; Sara Courtneidge; Sumit K Chanda; Minoru Fukuda
Journal:  Mol Biol Cell       Date:  2012-01-11       Impact factor: 4.138

8.  Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE.

Authors:  Daniel Beltrán-Valero de Bernabé; Kei-Ichiro Inamori; Takako Yoshida-Moriguchi; Christine J Weydert; Hollie A Harper; Tobias Willer; Michael D Henry; Kevin P Campbell
Journal:  J Biol Chem       Date:  2009-02-24       Impact factor: 5.157

9.  Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients.

Authors:  Claudio Coco; Gian Franco Zannoni; Emanuele Caredda; Stefano Sioletic; Alma Boninsegna; Mario Migaldi; Gianluca Rizzo; Luca Reggiani Bonetti; Giannicola Genovese; Egidio Stigliano; Achille Cittadini; Alessandro Sgambato
Journal:  J Exp Clin Cancer Res       Date:  2012-09-11

10.  VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer.

Authors:  Vassilis Aggelis; Rachel A Craven; Jianhe Peng; Patricia Harnden; Lana Schaffer; Gilberto E Hernandez; Steven R Head; Eamonn R Maher; Robert Tonge; Peter J Selby; Rosamonde E Banks
Journal:  Int J Oncol       Date:  2013-08-21       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.